Month: July 2007
US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz (aminolevulinic acid hydrochloride) topical…
(Bloomberg) — Wiz backer Sequoia Capital is poised to deliver a return of about 25 times its invested capital from…
US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz (aminolevulinic acid hydrochloride) topical…
(Bloomberg) — Wiz backer Sequoia Capital is poised to deliver a return of about 25 times its invested capital from…
US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz (aminolevulinic acid hydrochloride) topical…
(Bloomberg) — Wiz backer Sequoia Capital is poised to deliver a return of about 25 times its invested capital from…
US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz (aminolevulinic acid hydrochloride) topical…
(Bloomberg) — Wiz backer Sequoia Capital is poised to deliver a return of about 25 times its invested capital from…
US-based biopharmaceutical company Biofrontera has finished enrolling subjects in its multicentre Phase III trial of Ameluz (aminolevulinic acid hydrochloride) topical…
(Bloomberg) — Wiz backer Sequoia Capital is poised to deliver a return of about 25 times its invested capital from…